Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer by Ingle, James N
Page 1 of 4
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/10/S4/S17
Introduction
The clinician caring for women with early breast cancer is
keenly aware of the variability observed when endocrine
therapy with tamoxifen or the aromatase inhibitors (AIs) is
employed. This is seen in outcomes of the disease in terms of
recurrence but also, strikingly in some cases, in terms of
adverse events. This can be seen in the case of AIs, in which
some women develop disabling musculoskeletal events that
result in their discontinuing therapy, whereas the majority
develops no such adverse events. The same is true of other
adverse events such as deep venous thrombosis, endometrial
cancer and hot flashes in the case of tamoxifen. In the past,
the focus in selection of therapy for women with breast
cancer has been almost exclusively on the characteristics of
the tumour (for example, oestrogen receptor [ER] and human
epidermal growth factor receptor [HER]-2), with essentially
no attention given to the genetic make-up of the patient.
Pharmacogenetics and pharmacogenomics involve the study
of the role played by inheritance in individual variation in drug
response phenotypes such as disease outcomes and end
organ effects, including adverse events. These terms are
often used interchangeably but, strictly speaking, pharmaco-
genetics refers to the study of a gene or a number of genes,
such as those involved with a pathway, whereas pharmaco-
genomics involves the entire genome. We have truly entered
the era of pharmacogenomics with the introduction of genome-
wide association studies (GWASs). Pharmacogenetics/
pharmacogenomics have the clinical goals of better selecting
responsive patients, maximizing drug efficacy and minimizing
adverse reactions. Pharmacokinetics considers factors such
as metabolism and transport that influence drug concen-
trations at the target(s), whereas pharmacodynamics considers
factors that influence the response of the target(s), for
example receptors, enzymes, transporters and downstream
signalling molecules, to the drug.
Endocrine therapy represents the most important therapeutic
modality for those women whose tumours are potentially
endocrine sensitive, as indicated by expression of the ER
and/or progesterone receptor. The selective ER modulator
tamoxifen has been the most important therapeutic agent in
breast cancer for the past three decades. Tamoxifen has
received approval from the US Food and Drug Administration
for the full spectrum of breast cancer from metastatic disease
to those women who are at higher risk for developing breast
cancer. In addition, tamoxifen has received approval for
treatment of men with metastatic breast cancer and is
commonly used in the adjuvant setting. During the past
decade the third generation AIs anastrozole, exemestane and
letrozole have emerged as important additions to the
clinician’s armamentarium against breast cancer. They appear
to be more efficacious than tamoxifen in the advanced
disease setting [1], have become clearly established in the
adjuvant setting [2] and are a major focus of ongoing trials in
the prevention setting in postmenopausal women [3].
Tamoxifen and the AIs have recently become foci of intense
pharmacogenetic/pharmacogenomic research [4].
Tamoxifen
Interpatient variability exists in response to tamoxifen. The
accepted dose of tamoxifen is 20 mg/day, but there is
substantial variability with respect to levels of tamoxifen and
its metabolites. We examined steady-state levels of tamoxifen
and two of its major metabolites, namely 4-hydroxy-tamoxifen
(4HT) and N-desmethyl-tamoxifen, and found substantial
interpatient variability for all three; for instance, the median
level for tamoxifen after 6 weeks of therapy was 107 ng/ml,
with a range from 24 to 317 ng/ml [5]. These data raise the
question of whether one dose of tamoxifen ‘fits’ all patients. In
addition, there is variability in tolerance of this drug, with
differences in hot flashes, thromboembolic phenomena and
endometrial cancers as examples. Compliance with tamoxifen
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has become increasingly recognized as an important issue,
and a recent report [6] revealed that 49% discontinued
tamoxifen before the completion of 5 years. This poor com-
pliance is of concern because nonadherent patients lose the
therapeutic potential of this important drug.
For several decades, the tamoxifen metabolite 4HT has been
considered to be the important metabolite from a therapeutic
standpoint. Desta and coworkers [7] conducted a
comprehensive examination of tamoxifen and found that the
major primary metabolite of tamoxifen is N-desmethyl-
tamoxifen, in a reaction catalyzed by cytochrome P450
(CYP)3A4/5, whereas 4HT constitutes a minor metabolite,
with this reaction catalyzed by several CYP enzymes,
including CYP2D6. Importantly, N-desmethyl-tamoxifen is
converted to 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) by
CYP2D6. Endoxifen has been shown to have the same
binding affinity for ER-α as 4HT [6] and to be equipotent to
4HT in terms of inhibiting oestrogen-stimulated growth in ER-
positive breast cancer cell lines [8,9]. However, endoxifen is
normally present in substantially higher concentrations, up to
10 times greater, than 4HT in women taking the standard
dose of tamoxifen [10]. CYP2D6 is a highly polymorphic
gene, with alleles with normal activity, decreased activity or
no activity, and some cases of increased activity due to gene
duplication [11]. Endoxifen levels were found to be low in
those patients who had low activity CYP2D6 genotypes
and/or were receiving CYP2D6 inhibitors [12,13].
Goetz and colleagues [14] were the first to identify an
association between outcomes and CYP2D6 genotype in
patients receiving tamoxifen monotherapy for 5 years. This
retrospective study was performed in a well defined
population of postmenopausal women with early-stage breast
cancers whose tumours were known to be ER positive and
who had been enrolled on a prospective clinical trial that had
a median follow-up of 11.4 years [15]. Despite the relatively
small sample size (223 patients) and the inclusion of only the
*4 genotype, which underestimates the frequency of decreased
activity, the women homozygous for the *4 genotype (*4/*4)
had a worse relapse-free time and disease-free survival
compared with those women without this variant allele or who
carried only one (a heterozygous state [*4/wild type]).
Although these differences were significant in univariate
analyses, significance was lost in multivariate testing.
Goetz and colleagues [16] went on to collect information on
these patients relating to the concurrent use of medications
(selective serotonin reuptake inhibitors and the serotonin and
norepinephrine reuptake inhibitors) that have been shown to
inhibit CYP2D6 function [10,12,13]. When the genotype and
presence or absence of the CYP2D6 inhibitor were utilized to
determine a metabolizer phenotype, it was found in a
multivariate analysis that patients with decreased metabolism
had a significantly shorter time to recurrence and worse
relapse-free survival. Since these initial reports, four
additional studies have been reported that demonstrate an
association between CYP2D6 status and outcomes in
women receiving tamoxifen adjuvant therapy for early breast
cancer. These include studies from Germany [17], Japan
[18], the UK [19] and China [20].
Two groups had not identified CYP2D6 to have value in
predicting outcomes in women treated with tamoxifen [21-23].
Despite the weight of evidence shifting in support of a positive
value for CYP2D6 testing, the existence of conflicting data
has led to the establishment of the International Tamoxifen
Pharmacogenomics Consortium to collect and analyze the
worldwide experience. The Consortium data center is
PharmGKB (the Pharmacogenetics and Pharmacogenomics
Knowledge Base) located at Stanford University in the USA
[24]. This initiative is considered important in resolving the
important question of whether simple genotyping for CYP2D6
can provide clinically useful information regarding the
utilization of this commonly employed endocrine agent.
The fact that five studies have shown value for CYP2D6 is
remarkable, given the complexity of tamoxifen’s metabolism.
This metabolic complexity plus the multiple phase II enzymes
involved in glucuronidation and sulphate conjugation raises
the distinct possibility that additional genotypes will be
identified that could constitute a predictive panel that would
be of value in clinical decision making.
Aromatase inhibitors
The third-generation AIs anastrozole, exemestane and
letrozole have found widespread use in breast cancer. An
American Society of Clinical Oncology technology assess-
ment panel on AIs has concluded that optimal adjuvant
therapy for postmenopausal women with receptor positive
breast cancer includes an AI either as initial therapy or after
treatment with tamoxifen [25].
Considering the AI anastrozole, Partridge and coworkers [26]
examined adherence (defined as the proportion of days
patients had medications available over an observation
period) to this agent when given as adjuvant therapy for early
breast cancer. Patients with fewer than 80% of days were
considered nonadherent. This study of three health care
plans involved more than 12,000 patients. The mean adher-
ence ranged from 82% to 88% in year 1 and decreased to
625 to 79% in year 3. Thus, a substantial proportion of
women were suboptimally adherent to anastrozole therapy.
The variability in clinical tolerance to AIs raises the possibility
that genetic variability in patients plays a role. Research into
pharmacogenetic differences with the AIs is at an earlier
stage than with tamoxifen. However, Ma and colleagues [27]
sequenced the aromatase gene in 60 patients from each of
four ethnic groups (Caucasian-Americans, African-Americans,
Han Chinese-Americans and Mexican-Americans) and
identified 88 polymorphisms resulting in 44 haplotypes.Page 3 of 4
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Functional genomic studies were performed with four non-
synonymous coding single nucleotide polymorphisms that
were identified and a significant correlation between level of
activity and immunoreactive protein was found. Three of the
four coding single nucleotide polymorphisms had levels of
immunoreactive protein that was significantly lower than wild-
type aromatase enzyme. It is possible that patients with
decreased aromatase activity would have decreased potential
to benefit from the use of an AI. The findings of substantial
genetic variability in the aromatase gene within ethnic groups
and substantial variation between the four ethnic groups
provide a strong impetus to explore pharmacogenetics of AIs.
The era of pharmacogenomics of AIs has begun with the
development of a study to perform a GWAS in women
developing musculoskeletal events in a large clinical trial
evaluating AIs. This study is a part of a Global Alliance for
Pharmacogenomics between the US National Institutes of
Health Pharmacogenetics Research Network and the RIKEN
Center for Genomic Medicine in Japan [28], and involves the
Mayo Pharmacogenetics Research Network, the National
Cancer Institute of Canada Clinical Trials Group and RIKEN.
Whereas the initial studies will involve an evaluation of
adverse events, future studies are envisioned that will
examine breast cancer events.
Conclusion
The field of pharmacogenetics is at an early stage in the
endocrine therapy of breast cancer. The information that has
emerged with CYP2D6 appears to offer the potential to fulfill
the clinical goal of better selecting patients for whom
tamoxifen should be employed, but further validation is
needed before widespread acceptance. Pharmacogenetics/
genomics are at an earlier stage with the AIs. The era of
pharmacogenomics has been entered with the availability of
GWASs. It is anticipated that results will become available for
both tamoxifen and the AIs over the next several years. Com-
pliance with a drug is obviously multifactorial and includes
adverse events as only one factor. However, compliance is a
crucial consideration, because noncompliance with both
tamoxifen and AIs carries with it the loss of potential for
benefit from therapy. In endocrine therapy of breast cancer,
pharmacogenetics/pharmacogenomics offer the potential of
identifying the right drug at the right dose for the right patient.
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